The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer

被引:23
|
作者
Castro, Elena [1 ,2 ]
Mikropoulos, Christos [1 ,2 ]
Bancroft, Elizabeth K. [1 ,2 ]
Dadaev, Tokhir [1 ]
Goh, Chee [1 ,2 ]
Taylor, Natalie [1 ,2 ]
Saunders, Edward [1 ]
Borley, Nigel [2 ]
Keating, Diana [1 ]
Page, Elizabeth C. [1 ]
Saya, Sibel [1 ]
Hazell, Stephen [3 ]
Livni, Naomi [3 ]
deSouza, Nandita [4 ]
Neal, David [5 ,6 ]
Hamdy, Freddie C. [7 ]
Kumar, Pardeep [2 ]
Antoniou, Antonis C. [8 ]
Kote-Jarai, Zsofia [1 ]
Eeles, Rosalind A. [1 ,2 ]
机构
[1] Inst Canc Res, Oncogenet Team, London SW3 6JB, England
[2] Royal Marsden Natl Hlth Serv Fdn Trust, Acad Urol Unit, London, England
[3] Royal Marsden Natl Hlth Serv Fdn Trust, Histopathol Dept, London, England
[4] Inst Canc Res, Div Radiotherapy & Imaging, Sutton SM2 5NG, Surrey, England
[5] Canc Res UK Cambridge Inst, Dept Oncol, Cambridge, England
[6] Canc Res UK Cambridge Inst, Dept Surg, Cambridge, England
[7] Univ Oxford, Nuffield Dept Surg Sci, Oxford, England
[8] Univ Cambridge, Dept Publ Hlth & Primary Care, Ctr Canc Genet Epidemiol, Cambridge, England
来源
ONCOLOGIST | 2016年 / 21卷 / 06期
基金
加拿大健康研究院;
关键词
Prostate cancer; Family history; Single nucleotide polymorphisms; Prostate-specific antigen; GENETIC-VARIANTS; RISK; ANTIGEN; PREVALENCE; MARKERS; UTILITY; IMPACT;
D O I
10.1634/theoncologist.2015-0336
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. A better assessment of individualized prostate cancer (PrCa) risk is needed to improve screening. The use of the prostate-specific antigen (PSA) level for screening in the general population has limitations and is not currently advocated. Approximately 100 common single nucleotide polymorphisms (SNPs) have been identified that are associated with the risk of developing PrCa. The PROFILE pilot study explored the feasibility of using SNP profiling in men with a family history (FH) of PrCa to investigate the probability of detecting PrCa at prostate biopsy (PB). The primary aim of this pilot study was to determine the safety and feasibility of PrCa screening using transrectal ultrasound-guided PB with or without diffusion-weighted magnetic resonance imaging (DW-MRI) in men with a FH. A secondary aim was to evaluate the potential use of SNP profiling as a screening tool in this population. Patients and Methods. A total of 100 men aged 40-69 years with a FH of PrCa underwent PB, regardless of their baseline PSA level. Polygenic risk scores (PRSs) were calculated for each participant using 71 common PrCa susceptibility alleles. We treated the disease outcome at PB as the outcome variable and evaluated its associations with the PRS, PSA level, and DW-MRI findings using univariate logistic regression. Results. Of the 100 men, 25 were diagnosed with PrCa, of whom 12 (48%) had clinically significant disease. Four adverse events occurred and no deaths. The PSA level and age at study entry were associated with PrCa at PB (p = .00037 and p = .00004, respectively). Conclusion. The results of the present pilot study have demonstrated that PB is a feasible and safe method of PrCa screening in men with a FH, with a high proportion of PrCa identified requiring radical treatment. It is feasible to collect data on PrCa-risk SNPs to evaluate their combined effect as a potential screening tool. A larger prospective study powered to detect statistical associations is in progress.
引用
收藏
页码:716 / 722
页数:7
相关论文
共 50 条
  • [41] RACIAL DISPARITIES IN PSA SCREENING IN US MEN WITH FAMILY HISTORY OF PROSTATE CANCER: A CONTEMPORARY NATIONWIDE SURVEY
    Dalela, Deepansh
    Hanna, Renee
    Jamil, Marcus
    Sood, Akshay
    Keeley, Jacob
    Rogers, Craig
    Menon, Mani
    Abdollah, Firas
    [J]. JOURNAL OF UROLOGY, 2021, 206 : E852 - E853
  • [42] Development of a tailored, Online decision aid on screening options for unaffected men with a family history of prostate cancer
    Watts, K. J.
    Wakefield, C. E.
    Meiser, B.
    Barratt, A.
    Patel, M.
    Mann, G.
    Lobb, E.
    Howard, K.
    Gaff, C.
    Ramsay, J.
    [J]. PSYCHO-ONCOLOGY, 2008, 17 : S157 - S157
  • [43] Survival outcomes in men with a positive family history of prostate cancer: a registry based study
    Ang, Mann
    Borg, Martin
    O'Callaghan, Michael E.
    [J]. BMC CANCER, 2020, 20 (01)
  • [44] Use of complementary and alternative medicine in men with family history of prostate cancer: A pilot study
    Beebe-Dimmer, JL
    Wood, DP
    Gruber, SB
    Douglas, JA
    Bonner, JD
    Mohai, C
    Zuhlke, KA
    Shepherd, C
    Cooney, KA
    [J]. UROLOGY, 2004, 63 (02) : 282 - 287
  • [45] Survival outcomes in men with a positive family history of prostate cancer: a registry based study
    Mann Ang
    Martin Borg
    Michael E. O’Callaghan
    [J]. BMC Cancer, 20
  • [46] Temporal and Racial Trends in Prostate-specific Antigen Screening for U.S. Men With a Family History of Prostate Cancer
    Dalela, Deepansh
    Malchow, Taylor
    Butaney, Mohit
    Majdalany, Sami
    Corsi, Nicholas J.
    Rakic, Ivan
    Sood, Akshay
    Rogers, Craig
    Abdollah, Firas
    [J]. UROLOGY PRACTICE, 2023, 10 (05) : 484 - 492
  • [47] The cancer genetic service needs and preferences of men with a family history of prostate cancer
    Gaff, C. L.
    Cowan, R.
    Melser, B.
    Lindeman, G. J.
    [J]. PSYCHO-ONCOLOGY, 2006, 15 (02) : S108 - S109
  • [48] Prevalence and predictors of cancer specific distress in men with a family history of prostate cancer
    McDowell, M. E.
    Occhipinti, S.
    Gardiner, R. A.
    Chambers, S. K.
    [J]. PSYCHO-ONCOLOGY, 2013, 22 (11) : 2496 - 2504
  • [49] Web-Based Peer Navigation for Men with Prostate Cancer and Their Family Caregivers: A Pilot Feasibility Study
    Bender, Jacqueline L.
    Flora, Parminder K.
    Soheilipour, Shimae
    Dirlea, Mihaela
    Maharaj, Nandini
    Parvin, Lisa
    Matthew, Andrew
    Catton, Charles
    Jamnicky, Leah
    Pollock, Philip
    Kwan, Winkle
    Finelli, Antonio
    Kazanjian, Arminee
    [J]. CURRENT ONCOLOGY, 2022, 29 (06) : 4285 - 4299
  • [50] MORTALITY BENEFIT OF SCREENING MEN WITH A FAMILY HISTORY OF PROSTATE CANCER AS A SURROGATE FOR HIGH GENETIC RISK IN THE PLCO TRIAL
    Liss, Michael
    Hemal, Sij
    Krane, Spencer
    Kader, A. Karim
    [J]. JOURNAL OF UROLOGY, 2014, 191 (04): : E740 - E740